{"id":904119,"date":"2025-11-03T09:25:32","date_gmt":"2025-11-03T14:25:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/"},"modified":"2025-11-03T09:25:32","modified_gmt":"2025-11-03T14:25:32","slug":"dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/","title":{"rendered":"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment"},"content":{"rendered":"

\nThe project underscores Dar\u00e9 Bioscience\u2019s growing role in shaping the future of contraceptive innovation
\n<\/h2>\n
\n

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced a contract with the Gates Foundation under which it can receive up to approximately $300,000 to conduct a strategic landscape review of organizations with capabilities relevant to contraceptive product development.<\/p>\n

Under this contract, Dar\u00e9 will work to identify and assess for-profit and non-profit organizations worldwide with demonstrated capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products.<\/p>\n

\u201cWe are honored to be selected to receive funding from the Gates Foundation to help strengthen the global contraceptive innovation ecosystem,\u201d said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. \u201cDar\u00e9\u2019s mission is to close critical gaps in care using rigorous science and technologies that serve her needs. This initiative will help identify potential strategic partners for the foundation that can help to accelerate the translation of new contraceptive concepts into products that make a meaningful difference globally.\u201d<\/p>\n

\u201cThis initiative builds on Dar\u00e9\u2019s expertise in women\u2019s health product development and its track record of working with public and private sector collaborators to advance innovative contraceptive and reproductive health solutions,\u201d added Johnson.<\/p>\n

\n About Dar\u00e9 Bioscience<\/strong>\n <\/p>\n

Dar\u00e9 Bioscience is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Dar\u00e9 advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Dar\u00e9 is working to close critical gaps in care using science that serves her needs.<\/p>\n

For decades, women have been told to \u201cwait it out\u201d or \u201clive with it,\u201d while innovations that could improve their quality of life languish in the regulatory or funding pipeline.\u00a0\u00a0 With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to real, evidence-based solutions continues to lag. Dar\u00e9 was founded to change that. As a female-led health biotech company, Dar\u00e9 is accelerating the development of credible, science-based solutions that meet the high standards of clinical rigor \u2013 randomized, controlled trials; validated endpoints; peer-reviewed publications; and current Good Manufacturing Practice (cGMP) requirements.<\/p>\n

To learn more about Dar\u00e9\u2019s mission to deliver differentiated therapies for women and its innovation pipeline, please visit www.darebioscience.com.<\/p>\n

Dar\u00e9 Bioscience leadership has been named on the Medicine Maker\u2019s Power List and Endpoints News\u2019 Women in Biopharma and Dar\u00e9’s CEO has been honored as one of Fierce Pharma\u2019s Most Influential People in Biopharma for Dar\u00e9\u2019s contributions to innovation and advocacy in the women\u2019s health space.<\/p>\n

Dar\u00e9 may announce material information about its finances, products and product candidates, clinical trials and other matters using the Investors section of its website (http:\/\/ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar\u00e9 will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, products and product candidates, clinical trials and other matters. The information Dar\u00e9 posts on its investor relations website or through social media channels may be deemed to be material information. Dar\u00e9 encourages investors, the media, and others interested in the company to review the information Dar\u00e9 posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Dar\u00e9\u2019s website.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Dar\u00e9 cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccontemplate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cobjective,\u201d \u201con track,\u201d or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to the potential for Dar\u00e9 to receive up to approximately $300,000 in payments from the foundation under the new agreement and other potential benefits to Dar\u00e9 related to its performance under the agreement. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar\u00e9\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: Dar\u00e9\u2019s ability to successfully provide the required services and comply with its other obligations under its new agreement with the foundation, including due to factors outside of its control such as lack of engagement by the grantee organizations; Dar\u00e9\u2019s obligations to relinquish rights to deliverables resulting from its performance of services under the agreement and grant licenses to background materials incorporated into or required to be used with such deliverables to the foundation; the foundation\u2019s ability to terminate the agreement without cause; Dar\u00e9\u2019s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; Dar\u00e9\u2019s dependence on grants and other financial awards from governmental entities and the foundation; Dar\u00e9\u2019s reliance on third parties to execute its business strategy, including to develop products and bring solutions to market, and the risk that those third parties may not perform as expected; the loss of, or inability to attract, key personnel; Dar\u00e9\u2019s ability to adequately protect or enforce its, or its licensor\u2019s, intellectual property rights; product liability claims; governmental investigations or actions relating to Dar\u00e9\u2019s products or product candidates or the business activities of Dar\u00e9, its commercial collaborators or other third parties on which Dar\u00e9 relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Dar\u00e9\u2019s ability to raise additional capital or on Dar\u00e9\u2019s operations, financial results and condition, and ability to achieve current plans and objectives; Dar\u00e9\u2019s ability to maintain compliance with Nasdaq\u2019s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market; cybersecurity incidents or similar events that compromise Dar\u00e9\u2019s technology systems or those of third parties on which it relies and\/or significantly disrupt Dar\u00e9\u2019s business; and disputes or other developments concerning Dar\u00e9\u2019s intellectual property rights. Dar\u00e9\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar\u00e9\u2019s risks and uncertainties, you are encouraged to review its documents filed with the SEC including Dar\u00e9\u2019s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar\u00e9 undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Dar\u00e9 Bioscience Investor Relations<\/strong>
\n
\n
\n innovations@darebioscience.com<\/u>
\n <\/a>\n <\/p>\n

Source: Dar\u00e9 Bioscience, Inc.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The project underscores Dar\u00e9 Bioscience\u2019s growing role in shaping the future of contraceptive innovation SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced a contract with the Gates Foundation under which it can receive up to approximately $300,000 to conduct a strategic landscape review of organizations with capabilities relevant to contraceptive product development. Under this contract, Dar\u00e9 will work to identify and assess for-profit and non-profit organizations worldwide with demonstrated capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products. \u201cWe are honored to be selected to … <\/p>\n

Continue reading “Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904119","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The project underscores Dar\u00e9 Bioscience\u2019s growing role in shaping the future of contraceptive innovation SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced a contract with the Gates Foundation under which it can receive up to approximately $300,000 to conduct a strategic landscape review of organizations with capabilities relevant to contraceptive product development. Under this contract, Dar\u00e9 will work to identify and assess for-profit and non-profit organizations worldwide with demonstrated capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products. \u201cWe are honored to be selected to … Continue reading "Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T14:25:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment\",\"datePublished\":\"2025-11-03T14:25:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/\"},\"wordCount\":1271,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/\",\"name\":\"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=\",\"datePublished\":\"2025-11-03T14:25:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/","og_locale":"en_US","og_type":"article","og_title":"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - Market Newsdesk","og_description":"The project underscores Dar\u00e9 Bioscience\u2019s growing role in shaping the future of contraceptive innovation SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced a contract with the Gates Foundation under which it can receive up to approximately $300,000 to conduct a strategic landscape review of organizations with capabilities relevant to contraceptive product development. Under this contract, Dar\u00e9 will work to identify and assess for-profit and non-profit organizations worldwide with demonstrated capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products. \u201cWe are honored to be selected to … Continue reading \"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T14:25:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment","datePublished":"2025-11-03T14:25:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/"},"wordCount":1271,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/","name":"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=","datePublished":"2025-11-03T14:25:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzAwNCM3MjM5MTA4IzIwMDgzNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-to-receive-up-to-300000-to-conduct-global-contraceptive-innovation-capabilities-landscape-assessment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dar\u00e9 Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904119"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904119\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}